Q3 EPS Forecast for LB Pharmaceuticals Raised by Analyst

LB Pharmaceuticals Inc (NASDAQ:LBRX) – Research analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for LB Pharmaceuticals in a report issued on Monday, August 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.95) per share for the quarter, up from their prior forecast of ($0.97). HC Wainwright has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for LB Pharmaceuticals’ current full-year earnings is ($3.58) per share. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($3.51) EPS, Q1 2027 earnings at ($1.13) EPS, Q2 2027 earnings at ($1.19) EPS, Q3 2027 earnings at ($1.26) EPS, Q4 2027 earnings at ($1.29) EPS and FY2027 earnings at ($4.87) EPS.

Several other equities research analysts have also commented on LBRX. Wall Street Zen upgraded shares of LB Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. BMO Capital Markets began coverage on shares of LB Pharmaceuticals in a research note on Monday, July 20th. They issued an “outperform” rating and a $46.00 price objective for the company. Weiss Ratings upgraded LB Pharmaceuticals from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Friday, July 24th. Roth Capital reissued a “buy” rating and issued a $37.00 target price on shares of LB Pharmaceuticals in a report on Sunday, May 17th. Finally, Piper Sandler reissued an “overweight” rating and issued a $78.00 target price on shares of LB Pharmaceuticals in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, LB Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $45.12.

LB Pharmaceuticals Trading Up 5.0%

Shares of NASDAQ:LBRX opened at $45.00 on Wednesday. The firm has a 50 day simple moving average of $32.10 and a 200-day simple moving average of $28.05. LB Pharmaceuticals has a twelve month low of $13.36 and a twelve month high of $46.01. The company has a market capitalization of $1.29 billion and a PE ratio of -26.01.

LB Pharmaceuticals (NASDAQ:LBRX) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.08.

Institutional Investors Weigh In On LB Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System acquired a new stake in shares of LB Pharmaceuticals during the fourth quarter worth about $26,000. Bank of America Corp DE acquired a new position in LB Pharmaceuticals in the 3rd quarter valued at about $27,000. Russell Investments Group Ltd. purchased a new stake in LB Pharmaceuticals during the 4th quarter valued at approximately $34,000. Strs Ohio acquired a new stake in LB Pharmaceuticals during the 4th quarter worth approximately $76,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of LB Pharmaceuticals in the 4th quarter valued at approximately $91,000.

About LB Pharmaceuticals

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.